Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
- PMID: 20190329
- DOI: 10.1183/09031936.00077309
Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
Abstract
Several clinical trials have recently targeted specific pathways implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). However, IPF remains plagued by a median survival of 3 yrs and emphasises the need for further research with new insights and perspectives. The prevailing pathogenic hypotheses assume that either an inflammatory process or an independent epithelial/fibroblastic disorder may propagate the disease process. Based on knowledge developed with considerable scientific evidence, we provide our perspectives with an alternative point of view that IPF be considered as a neoproliferative disorder of the lung. Genetic alterations, response to growth and inhibitory signals, resistance to apoptosis, myofibroblast origin and behaviour, altered cellular communications, and intracellular signalling pathways are all fundamental pathogenic hallmarks of both IPF and cancer. The concept of IPF as a lethal malignant disorder of the lung might extend beyond the pathogenic link between these two diseases and disclose new pathogenic mechanisms leading to novel therapeutic options, adopted from cancer biology. Moreover, this vision might dawn the awareness of the public, political and scientific community of this devastating disease from an angle different from the current perception and provoke new ideas and studies to get a better understanding to control the otherwise relentless progressive disease.
Similar articles
-
Idiopathic pulmonary fibrosis: an altered fibroblast proliferation linked to cancer biology.Proc Am Thorac Soc. 2012 Jul;9(3):153-7. doi: 10.1513/pats.201203-025AW. Proc Am Thorac Soc. 2012. PMID: 22802290
-
A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer.Eur Respir J. 2013 Feb;41(2):262-9. doi: 10.1183/09031936.00115112. Epub 2012 Aug 16. Eur Respir J. 2013. PMID: 22903965
-
Emerging therapeutic interventions for idiopathic pulmonary fibrosis.Expert Opin Investig Drugs. 2014 Jul;23(7):893-910. doi: 10.1517/13543784.2014.913569. Epub 2014 Apr 28. Expert Opin Investig Drugs. 2014. PMID: 24766571 Review.
-
Idiopathic pulmonary fibrosis and cancer: do they really look similar?BMC Med. 2015 Sep 24;13:220. doi: 10.1186/s12916-015-0478-1. BMC Med. 2015. PMID: 26399408 Free PMC article.
-
Common pathways in idiopathic pulmonary fibrosis and cancer.Eur Respir Rev. 2013 Sep 1;22(129):265-72. doi: 10.1183/09059180.00003613. Eur Respir Rev. 2013. PMID: 23997054 Free PMC article. Review.
Cited by
-
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.Eur Respir J. 2015 May;45(5):1434-45. doi: 10.1183/09031936.00174914. Epub 2015 Mar 5. Eur Respir J. 2015. PMID: 25745043 Free PMC article. Review.
-
Plasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis.Int J Mol Sci. 2022 Sep 28;23(19):11443. doi: 10.3390/ijms231911443. Int J Mol Sci. 2022. PMID: 36232756 Free PMC article. Review.
-
Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis.JCI Insight. 2016 Apr 21;1(5):e86375. doi: 10.1172/jci.insight.86375. JCI Insight. 2016. PMID: 27275013 Free PMC article.
-
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes.Eur Respir Rev. 2012 Jun 1;21(124):161-7. doi: 10.1183/09059180.00001112. Eur Respir Rev. 2012. PMID: 22654089 Free PMC article. Review.
-
Significant accumulation of KRAS mutations in bronchiolar metaplasia-associated honeycomb lesions of interstitial pneumonia.Oncol Lett. 2022 May 26;24(1):225. doi: 10.3892/ol.2022.13346. eCollection 2022 Jul. Oncol Lett. 2022. PMID: 35720499 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources